Острый инфаркт миокарда как осложнение коронавирусной инфекции (клиническое наблюдение)

Coronavirus infection caused by the SARS-CoV-2 virus is a multifaceted disease due to generalized vascular endothelial damage. Endothelial damage also underlies COVID-associated coagulopathy.The paper presents a case of coagulopathy causing myocardial infarction in a 43-year-old patient with no history of coronary disease. We have reviewed the available literature for the pathophysiological rationale of the assumed possibility of coronary thrombosis resulting from coagulopathy with the intact intima of the coronary arteries.Conclusion. The present observation of coronary thrombosis with radiographically intact coronary artery intima confirms the important role of coronavirus infection in triggering endothelial dysfunction. Currently, the most effective strategy for this type of coronary lesions is the use of anticoagulants and antiplatelet agents along with ECG, echocardiography and troponin level monitoring.Коронавирусная инфекция, вызываемая вирусом SARS-CoV-2, является полиморфным заболеванием за счет генерализованного поражения эндотелия сосудов. Повреждение эндотелия лежит в основе ковид-ассоциированной коагулопатии.Привели наблюдение подобной коагулопатии, которая стала причиной острого инфаркта миокарда у 43-летнего мужчины без предшествующего коронарного анамнеза. Выполнили анализ доступных литературных источников на предмет патофизиологического обоснования гипотезы о возможности коронарного тромбоза как исхода ковид-ассоциированной коагулопатии при интактной интиме коронарных артерий.Заключение. Приведенное наблюдение подтверждает важную роль коронавирусной инфекциив запуске эндотелиальной дисфункции на примере коронарного тромбоза при рентгенологически интактной интиме венечных артерий. В настоящий момент наиболее эффективной тактикой при данном виде поражения коронарного русла остается антикоагулянтная и антиагрегантная терапия под контролем электрокардиографической, эхокардиографической картины и динамики тропонина

Toward personalization of asthma treatment according to trigger factors

Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma

Toward personalization of asthma treatment according to trigger factors

Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma. © 2020 The Author

Toward personalization of asthma treatment according to trigger factors

© 2020 The Authors Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma